Wynter Kipgen, MD
Endocrinology, Diabetes & Metabolism · Stillwater, OKNPI 1366434300
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Ascendis Pharma Endocrinology Inc accounts for 65.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $7,424 and has fallen 99.4% since, to $48 in 2024.
Across 218 payments — averaging $47.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$7K
- AstraZeneca$666
- Lilly USA, LLC$432
- Boehringer Ingelheim$318
- Novo Nordisk$314
- Sanofi-aventis U.S. LLC$275
- plus $2K from 25 others
Across 5 payments — averaging $2393.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Sanofi US Services Inc.$1K
- Merck$169
What the payments were for
- Speaking & faculty fees$5,27951%
- Travel & lodging$1,13111%
- Food & beverage$3,92938%
- Education$220%
- Gifts$591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 9 | $6,780 |
| AstraZeneca(2 entities) | 33 | $666 |
| Lilly USA, LLC | 34 | $432 |
| Boehringer Ingelheim | 21 | $318 |
| Novo Nordisk | 11 | $314 |
| Sanofi-aventis U.S. LLC | 17 | $275 |
| Xeris Pharmaceuticals, Inc. | 8 | $164 |
| Tandem Diabetes Care, Inc. | 8 | $159 |
| Ultragenyx Pharmaceutical Inc. | 8 | $140 |
| Recordati_rare_diseases_inc. | 6 | $125 |
| Insulet Corporation | 8 | $124 |
| Mannkind Corporation | 3 | $103 |
| Clarus Therapeutics Inc. | 7 | $80 |
| Medtronic | 4 | $77 |
| Corcept Therapeutics | 5 | $77 |
| IBSA Pharma Inc. | 5 | $71 |
| Bayer | 3 | $66 |
| AbbVie | 4 | $63 |
| Merck | 4 | $62 |
| Vistapharm, Inc. | 3 | $49 |
| Dexcom, Inc. | 3 | $48 |
| EUSA Pharma (US) LLC | 3 | $43 |
| Johnson & Johnson | 2 | $32 |
| Ascensia Diabetes Care US Inc. | 1 | $26 |
| Cequr Corporation | 2 | $26 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Abbott | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Macrilen$148
How this compares
$10,420 in reported general payments places this provider in the 80th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 28 | $32,334 |
| JardianceEmpagliflozin | 26 | $20,214 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $15,059 |
| OzempicSemaglutide | 11 | $13,332 |
| JanuviaSitagliptin Phosphate | 16 | $12,537 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,267 |
| SynthroidLevothyroxine Sodium | 25 | $1,428 |
| Ibandronate Sodium | 16 | $1,397 |
| Ultra-Fine Micro Pen NeedlePen Needle, Diabetic | 18 | $1,358 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 11 | $1,191 |
| Levothyroxine Sodium | 112 | $1,095 |
| Gabapentin | 41 | $714 |
| Atorvastatin Calcium | 17 | $360 |
| Metformin Hcl ErMetformin Hcl | 45 | $358 |
| Losartan Potassium | 19 | $321 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $432 | $32,33428 claims |
| Boehringer IngelheimJardiance | $318 | $20,21426 claims |
| Novo NordiskOzempic | $314 | $13,33211 claims |
| MerckJanuvia | $62 | $12,53716 claims |
| AbbVieSynthroid | $63 | $1,42825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Stillwater
- Cassie SmithEdmond$629K
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Matthew DraelosEdmond$110K
- Christian MangrumOklahoma City$54K
- Vaqar AhmadMidwest City$27K
- Hanna FoggTulsa$25K
- Mario Bustos RodriguezTulsa$19K
- Robert ScofieldOklahoma City$15K
- Lubna MirzaNorman$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.